Literature DB >> 9012555

Principles of drug administration in renal insufficiency.

Y W Lam1, S Banerji, C Hatfield, R L Talbert.   

Abstract

Normal renal function is important for the excretion and metabolism of many drugs. Renal diseases which affect glomerular blood flow and filtration, tubular secretion, reabsorption and renal parenchymal mass alter drug clearances and lead to the need for alterations in dosage regimens to optimise therapeutic outcome and minimise the risk of toxicity. Renal disease is increasing and the cost of care has risen progressively over the past decade. Part of these costs is related to inappropriate drug therapy and excessive drug use. Although there are a variety of methods for evaluating the various aspects of renal function, the most practical and commonly used clinical measure of renal function is estimated creatinine clearance (CLCR) as a marker for glomerular filtration. This is useful since alterations in drug clearance are proportional to alterations in CLCR, and this relationship is used as the basis for changing doses and dosage intervals for drugs which are largely renally excreted. Two populations, neonates and the elderly, are at risk of inappropriate drug dosage due to physiological changes in renal function. Estimated CLCR may not be the best method of evaluating renal function in these patients, and dosage regimens should be carefully considered. Renal insufficiency and concurrent drug therapy used in these populations can either increase or decrease drug absorption, depending on the particular agent. Drug distribution may be altered in renal insufficiency due to pH-dependent protein binding and reduced protein (primarily albumin) levels. Interestingly, renal disease may affect hepatic as well as renal drug metabolism; the exact mechanisms for these changes are not well understood. The most important quantitative pharmacokinetic change is excretion. Glomerular filtration and tubular process may both be affected but not to the same extent, and the type of renal disease may differentially affect filtration and excretion. Drug removal by dialysis is dependent on a number of factors, including the characteristics of a particular drug and the type of dialysis and equipment used. Therapeutic outcomes may be evaluated using end-points such as plasma concentrations, patient outcomes such as reduction in fever or negative cultures, and system-wide changes such as drug-use or laboratory-use patterns.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9012555     DOI: 10.2165/00003088-199732010-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  98 in total

1.  Effect of probenecid on the pharmacokinetics and pharmacodynamics of procainamide.

Authors:  Y W Lam; R A Boyd; S K Chin; D Chang; K M Giacomini
Journal:  J Clin Pharmacol       Date:  1991-05       Impact factor: 3.126

2.  Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers.

Authors:  D M Lanese; P S Alfrey; B A Molitoris
Journal:  Kidney Int       Date:  1989-06       Impact factor: 10.612

3.  Fractional excretion of uric acid in infancy and childhood. Index of tubular maturation.

Authors:  J H Passwell; M Modan; M Brish; S Orda; H Boichis
Journal:  Arch Dis Child       Date:  1974-11       Impact factor: 3.791

Review 4.  Mechanism of bactericidal action of aminoglycosides.

Authors:  B D Davis
Journal:  Microbiol Rev       Date:  1987-09

5.  Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function.

Authors:  D R Guay; G R Matzke; H N Bockbrader; J Dancik
Journal:  Clin Pharm       Date:  1983 Mar-Apr

6.  Hepatic drug metabolism in rats with experimental chronic renal failure.

Authors:  S E Patterson; V H Cohn
Journal:  Biochem Pharmacol       Date:  1984-03-01       Impact factor: 5.858

7.  Creatinine clearance: an inadequate marker of renal filtration in patients with early posthepatitic cirrhosis (Child A) without fluid retention and muscle wasting.

Authors:  N G DeSanto; P Anastasio; C Loguercio; L Spitali; C Del Vecchio Blanco; M Corvinelli; M Cirillo
Journal:  Nephron       Date:  1995       Impact factor: 2.847

8.  Aging and renal clearance of procainamide and acetylprocainamide.

Authors:  M M Reidenberg; M Camacho; J Kluger; D E Drayer
Journal:  Clin Pharmacol Ther       Date:  1980-12       Impact factor: 6.875

9.  Gentamicin dosing errors with four commonly used nomograms.

Authors:  T S Lesar; J C Rotschafer; L M Strand; L D Solem; D E Zaske
Journal:  JAMA       Date:  1982-09-10       Impact factor: 56.272

10.  Absence of tobramycin pharmacokinetic and creatinine clearance variation during the menstrual cycle: implied absence of variation in glomerular filtration rate.

Authors:  A N Nafziger; M S Schwartzman; J S Bertino
Journal:  J Clin Pharmacol       Date:  1989-08       Impact factor: 3.126

View more
  34 in total

1.  Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis.

Authors:  Silke C Mueller; Jolanta Majcher-Peszynska; Heiko Hickstein; Astrid Francke; Annette Pertschy; Martin Schulz; Ralf Mundkowski; Bernd Drewelow
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 2.  Nephrology: 3. Safe drug prescribing for patients with renal insufficiency.

Authors:  Joanne Kappel; Piera Calissi
Journal:  CMAJ       Date:  2002-02-19       Impact factor: 8.262

3.  Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.

Authors:  Kashyap Patel; Jason A Roberts; Jeffrey Lipman; Susan E Tett; Megan E Deldot; Carl M Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

4.  Downregulation of hepatic acetylation of drugs in chronic renal failure.

Authors:  Emilie Simard; Judith Naud; Josée Michaud; Francois A Leblond; Alain Bonnardeaux; Chantal Guillemette; Edith Sim; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

Review 5.  Extracorporeal Removal of Poisons and Toxins.

Authors:  Joshua David King; Moritz H Kern; Bernard G Jaar
Journal:  Clin J Am Soc Nephrol       Date:  2019-08-22       Impact factor: 8.237

Review 6.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

7.  A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients.

Authors:  Daniel Moj; Hugo Maas; André Schaeftlein; Nina Hanke; José David Gómez-Mantilla; Thorsten Lehr
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

8.  Moderate renal dysfunction may not require a cisplatin dose reduction: a retrospective study of cancer patients with renal impairment.

Authors:  Tomoko Ogawa; Seiji Niho; Shunji Nagai; Takashi Kojima; Yoshiko Nishimura; Yuichiro Ohe; Naoki Kondo; Takuhiro Yamaguchi; Kazushi Endo; Keishiro Izumi; Hironobu Minami
Journal:  Int J Clin Oncol       Date:  2012-10-05       Impact factor: 3.402

Review 9.  A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD.

Authors:  Thomas D Nolin
Journal:  Semin Dial       Date:  2015-04-08       Impact factor: 3.455

10.  Psychiatric issues in renal failure and dialysis.

Authors:  A De Sousa
Journal:  Indian J Nephrol       Date:  2008-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.